Rep. Jefferson Shreve Sells Off Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Representative Jefferson Shreve (R-Indiana) recently sold shares of Charles River Laboratories International, Inc. NYSE: CRL. In a filing disclosed on June 22nd, the Representative disclosed that they had sold between $15,001 and $50,000 in Charles River Laboratories International stock on May 12th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Hubbell NYSE: HUBB on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Trane Technologies NYSE: TT on 5/12/2025.
• Sold $15,001 - $50,000 in shares of RTX NYSE: RTX on 5/12/2025.
• Sold $50,001 - $100,000 in shares of NiSource NYSE: NI on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Johnson & Johnson NYSE: JNJ on 5/12/2025.
• Sold $15,001 - $50,000 in shares of AppLovin NASDAQ: APP on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Fiserv NYSE: FI on 5/12/2025.
• Sold $15,001 - $50,000 in shares of CNO Financial Group NYSE: CNO on 5/12/2025.
• Sold $50,001 - $100,000 in shares of Cboe Global Markets NASDAQ: CBOE on 5/12/2025.
• Sold $15,001 - $50,000 in shares of Lam Research NASDAQ: LRCX on 5/12/2025.

Charles River Laboratories International Trading Down 0.3%

NYSE CRL traded down $0.56 during trading on Friday, reaching $176.54. 366,462 shares of the stock traded hands, compared to its average volume of 1,306,250. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The company has a quick ratio of 1.16, a current ratio of 1.43 and a debt-to-equity ratio of 0.78. The firm has a market cap of $8.67 billion, a price-to-earnings ratio of -271.59, a price-to-earnings-growth ratio of 5.68 and a beta of 1.49. The stock's 50-day moving average price is $149.28 and its 200 day moving average price is $150.23.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. During the same quarter in the prior year, the company earned $2.27 EPS. The firm's quarterly revenue was down 2.7% on a year-over-year basis. Analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on CRL. Evercore ISI upped their price target on Charles River Laboratories International from $170.00 to $180.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 9th. Barclays lifted their target price on Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research report on Thursday, May 8th. Citigroup raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and increased their price target for the company from $150.00 to $200.00 in a research report on Wednesday, July 9th. Mizuho dropped their price objective on Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. Finally, Wall Street Zen cut shares of Charles River Laboratories International from a "buy" rating to a "hold" rating in a research note on Saturday, July 5th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $174.54.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president directly owned 19,513 shares of the company's stock, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Handelsbanken Fonder AB increased its position in Charles River Laboratories International by 1.6% in the 4th quarter. Handelsbanken Fonder AB now owns 12,437 shares of the medical research company's stock valued at $2,296,000 after buying an additional 200 shares in the last quarter. Olympiad Research LP acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $267,000. Fjarde AP Fonden Fourth Swedish National Pension Fund lifted its holdings in shares of Charles River Laboratories International by 74.6% in the 4th quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 9,830 shares of the medical research company's stock worth $1,815,000 after purchasing an additional 4,200 shares in the last quarter. Illinois Municipal Retirement Fund acquired a new stake in Charles River Laboratories International in the 4th quarter valued at $2,510,000. Finally, Proficio Capital Partners LLC bought a new stake in Charles River Laboratories International during the 4th quarter valued at $10,768,000. 98.91% of the stock is owned by institutional investors and hedge funds.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).